West Valley City, Utah–based Scientia says the money will enable it to continue commercializing what company officials describe as the next generation of neurovascular tools, providing new ways to treat a variety of neurovascular disease states.
Piper Sandler Merchant Banking led the latest funding round.
“Scientia exemplifies many of the attributes we look for in an investment partner: a strong team with a long track record of innovation and success, differentiated and groundbreaking technology that improves patient outcomes, a large and growing market opportunity and strong financial performance,” Tom Schnettler, managing director at Piper Sandler Merchant Banking, said in a news release.
Scientia Vascular officials consider the company a disruptor in the neurovascular device space with its use of microfabrication in manufacturing. The company presently offers a portfolio of neurovascular guidewires, and it has applied the same manufacturing technologies, design principles, and precision machinery to develop highly differentiated microcatheters and aspiration catheters.
As Scientia moves ahead, microfabrication will continue to serve as the platform for innovating neurovascular disease treatment technologies, according to the company.
Said Scientia Vascular CEO John Lippert: “Our mission at Scientia is to develop and apply state-of-the-art technology to care for patients with unmet needs. We are grateful for the support of Piper Sandler Merchant Banking as we look to accelerate our growth following the launch of our Plato 17 and Socrates 38 neurovascular catheters.”
